Mark E Bangs

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:407-20. 2007
  2. doi request reprint Meta-analysis of suicide-related behavior events in patients treated with atomoxetine
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 47:209-18. 2008
  3. doi request reprint Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder
    Mark E Bangs
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pediatrics 121:e314-20. 2008
  4. ncbi request reprint Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Saf 31:345-54. 2008
  5. ncbi request reprint Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD
    John Polzer
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 61:713-9. 2007
  6. ncbi request reprint Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine
    Joachim F Wernicke
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    Dev Med Child Neurol 49:498-502. 2007
  7. doi request reprint Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial
    Paula T Trzepacz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 27:45-52. 2011
  8. pmc Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele
    Yi M Cui
    Department of Pharmacy, Peking University First Hospital, Beijing, PR China
    Br J Clin Pharmacol 64:445-9. 2007
  9. ncbi request reprint Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 29:1168-77. 2007

Detail Information

Publications9

  1. ncbi request reprint Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
    J Child Adolesc Psychopharmacol 17:407-20. 2007
    ..ATX was an effective and safe treatment for ADHD in adolescents with ADHD and MDD. However, this trial showed no evidence for ATX of efficacy in treating MDD...
  2. doi request reprint Meta-analysis of suicide-related behavior events in patients treated with atomoxetine
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Am Acad Child Adolesc Psychiatry 47:209-18. 2008
    ..The present work examined suicide-related events in acute, double-blind, and placebo- or active comparator-controlled trials with atomoxetine...
  3. doi request reprint Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder
    Mark E Bangs
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Pediatrics 121:e314-20. 2008
    ..In this study we examined the effectiveness of atomoxetine for the treatment of oppositional defiant disorder comorbid with attention-deficit/hyperactivity disorder...
  4. ncbi request reprint Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder
    Mark E Bangs
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    Drug Saf 31:345-54. 2008
    ..This study describes and assesses potential hepatobiliary events related to atomoxetine therapy, as reported in clinical trials and as spontaneous adverse event reports post-launch in 2002...
  5. ncbi request reprint Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD
    John Polzer
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Biol Psychiatry 61:713-9. 2007
    ..We systematically examined potential aggression/hostility-related events in a meta-analysis of acute clinical trials of atomoxetine for attention-deficit/hyperactivity disorder (ADHD)...
  6. ncbi request reprint Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine
    Joachim F Wernicke
    Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
    Dev Med Child Neurol 49:498-502. 2007
    ..The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD...
  7. doi request reprint Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial
    Paula T Trzepacz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Curr Med Res Opin 27:45-52. 2011
    ....
  8. pmc Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele
    Yi M Cui
    Department of Pharmacy, Peking University First Hospital, Beijing, PR China
    Br J Clin Pharmacol 64:445-9. 2007
    ..To characterize atomoxetine pharmacokinetics, explore the effect of the homozygous CYP2D6*10 genotype on atomoxetine pharmacokinetics and evaluate the tolerability of atomoxetine, in healthy Chinese subjects...
  9. ncbi request reprint Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study
    Humberto Quintana
    Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    Clin Ther 29:1168-77. 2007
    ..Recently developed nonpsychostimulant treatments have allowed certain patients to switch from a psychostimulant to a nonpsychostimulant. However, the outcomes of such switches have not been systematically studied...